Exploring the Successes and Failures of Inhaled Surfactant in the Utility of Current Surfactant Aerosol Delivery Systems

Time: 3:00 pm
day: Day 2


  • With the exception of FDA approvals for surfactant delivery for pre-term infants and neonates, this therapeutic modality has not delivered consistent results in the management of surfactant deficiency conditions
  • Addressing barriers: what has hindered the addition of surfactant delivery to the therapeutic armamentarium?
  • Enhancing aerosol delivery: what enhancements are needed to make surfactant a valuable treatment across various diseases like ARDS and COPD?